The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Clinical evaluation of percutaneous coronary intervention and influence of β-adrenergic blocker on female patients with coronary heart disease
Author(s): 
Pages: 98-101,105
Year: Issue:  4
Journal: Acta Academiae Medicinae Shandong

Keyword:  Coronary arteriosclerosisFemaleβ adrenergic blockerPercutaneous coronary intervention;
Abstract: 目的探讨女性冠心病经皮冠状动脉介入治疗(PCI)的临床特点及PCI治疗前服用β-受体阻滞剂对患者的保护作用。方法选择冠心病患者,男191例作为男性组,女75例作为女性组,均于PCI治疗前服用β-受体阻滞剂,同时收集拟行PCI的女性患者50例,术前及术后均未服用β-受体阻滞剂。所有患者均行PCI,并抽取肘静脉血测定肾上腺素(E)、去甲肾上腺素(NE)、肌酸磷酸激酶同工酶(CK-MB)及肌钙蛋白T(TNT)。结果与男性组比较,女性组的多支病变明显增高(P均<0.05),PCI术后出血事件、肾功能衰竭及死亡率等并发症均显著增加(P均<0.05)。与服用β-受体阻滞剂女性组比较,未服用药物的患者PCI术前和术后E(P<0.01)、NE(P<0.05)均明显增高,术后CK-MB和TNT均显著增高(P均<0.01);其心血管事件(MACE)、心绞痛、心律失常、出血事件的发生率和死亡率均显著升高。结论女性患者冠心病病情及PCI术后较男性严重,提前服用β-受体阻滞剂具有保护作用。
Related Articles
No related articles found